期刊
CELL DEATH & DISEASE
卷 13, 期 5, 页码 -出版社
SPRINGERNATURE
DOI: 10.1038/s41419-022-04967-7
关键词
-
类别
资金
- National Natural Science Foundation of China [NSFC-U1504818]
- Scientific and technological project in Henan Province [222102310134]
- Medical Science and Technique Foundation of Henan Province [SBGJ202002097]
XRCC2-deficient colorectal cancer (CRC) shows increased sensitivity to PARP inhibitors after radiotherapy, supporting the clinical application of olaparib as a radiosensitizer for treating XRCC2-deficient CRC.
The use of PARP inhibitors in combination with radiotherapy is a promising strategy to locally enhance DNA damage in tumors. Loss of XRCC2 compromises DNA damage repairs, and induced DNA damage burdens may increase the reliance on PARP-dependent DNA repairs of cancer cells to render cell susceptibility to PARP inhibitor therapy. Here we tested the hypothesis that XRCC2 loss sensitizes colorectal cancer (CRC) to PARP inhibitor in combination with radiotherapy (RT). We show that high levels of XRCC2 or PARP1 in LARC patients were significantly associated with poor overall survival (OS). Co-expression analyses found that low levels of PARP1 and XRCC2 were associated with better OS. Our in vitro experiments indicated that olaparib+IR led to reduced clonogenic survival, more DNA damage, and longer durations of cell cycle arrest and senescence in XRCC2-deficient cells relative to wild-type cells. Furthermore, our mouse xenograft experiments indicated that RT + olaparib had greater anti-tumor effects and led to long-term remission in mice with XRCC2-deficient tumors. These findings suggest that XRCC2-deficient CRC acquires high sensitivity to PARP inhibition after IR treatment and supports the clinical development for the use of olaparib as a radiosensitizer for treatment of XRCC2-deficient CRC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据